Diabetes Mellitus
Conditions
Brief summary
To quantify the local prevalence of diabetes mellitus in critically ill patients. To understand whether a correlation does exist between premorbid glycaemic control and glycaemic status in ICU. A subgroup analysis will be conducted to investigate whether a relationship does exist between Neuron Specific Enolase levels and glycaemic disorders.
Detailed description
The aim of this study is to determine the local prevalence of critical illness-associated hyperglycaemia (CIAH) and recognised and unrecognised diabetes, as well as to evaluate how premorbid glycaemia impacts the relationship between three glycaemic domains and mortality. The investigators will calculate the Time In Range (TIR, 70-180 mg/dl) and evaluate distribution of percentage time in range for non-diabetics and diabetics patients, in order to understand the association between TIR and survival in both groups of patients (patients with diabetes and patients without diabetes). In view of the potential adverse effects of hyperglycaemia, hypoglycaemia and glycaemic variability on the brain, the investigators will dose Neuron Specific Enolase in critically ill patients. The aim is to define if a biochemical correlation does exist between critically ill dysglycaemia and NSE plasma concentration.
Interventions
None listed
Sponsors
Catholic University of the Sacred Heart
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ICU patients * expected ICU length of stay \> 48 hours
Exclusion criteria
* age \<18 years * ICU length of stay \<48 hours * diabetic ketoacidosis * hyperosmolar nonketonic hyperglycaemia syndrome * pregnancy * hypoglycaemic coma * acute or acute on chronic liver failure, liver transplantation or end-stage liver disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in glycaemic blood levels during ICU stay | Glycaemic values expressed as mean glycaemia will be collected at the baseline and every 8 hours for the duration of ICU stay, expected average of 10 days per patient. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Episodes of hyperglycaemia (number) | For the duration of ICU stay, expected average of 10 days per patient. | — |
| Coefficient of variation of blood glucose levels | Time point A:24 hours. Time point B: 48 hours after ICU admission. Time point C: for the duration of ICU stay, an expected average of 10 days per patient. | Coefficient of Variation, calculated as a percentage |
| Time in glycaemic Range (TIR) | Time point A:24 hours. Time point B: 48 hours after ICU admission. Time point C: for the duration of ICU stay, an expected average of 10 days per patient. | Evaluated in hours TIR/ total hours in ICU; calculated as a percentage |
| Episodes of hypoglicaemia (number) | For the duration of ICU stay, expected average of 10 days per patient. | — |
| Days of continuous renal replacement therapy | Participants will be followed for the duration of ICU stay, expected average per patient: 10 days | — |
| Neuron Specific Enolase (NSE) blood levels and glycaemic disorders | NSE collection: Time point A: ICU admission. Time point NSE: 48-72 hours after ICU admission | To detect a correlation between NSE levels and glycaemic alterations in both diabetic and non diabetic patients. |
| Days of mechanical ventilation | Participants will be followed for the duration of ICU stay, expected average per patient: 10 days | — |
Contacts
Primary ContactFrancesca Di Muzio
Outcome results
None listed